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Abstract
Background: Gastrointestinal stromal tumors (GISTs), the most common type of mesenchymal
tumors of the gastrointestinal (GI) tract, demonstrate positive kit staining. We report our surgical
experience with 100 small intestine GIST patients and identify predictors for long-term disease-free
survival (DFS) and overall survival (OS) to clarify the difference between high- and low-risk patients.
Methods: The clinicopathologic and follow-up records of 100 small intestine GIST patients who
were treated at Chung Gung Memorial Hospital between 1983 and 2002 were retrospectively
reviewed. Clinical and pathological factors were assessed for long-term DFS and OS by using a
univariate log-rank test and a multivariate Cox proportional hazard model.
Results: The patients included 52 men and 48 women. Their ages ranged from 27 to 82 years.
Among the 85 patients who underwent curative resection, 44 (51.8%) developed disease
recurrence (liver metastasis was the most common form of recurrence). The follow-up period
ranged from 5 to 202 months (median: 33.2 months). The 1-, 3-, and 5-year DFS and OS rates were
85.2%, 53.8%, and 43.7%, and 91.5%, 66.6%, and 50.5%, respectively. Using multivariate analysis, it
was found that high tumor cellularity, mitotic count >5/50 high-power field, and a Ki-67 index
10% were three independent factors that were inversely associated with DFS. However, absence
of tumor perforation, mitotic count < 5/50 high power field, and tumor with low cellularity were
predictors of long-term favorable OS.
Conclusion: Tumors with low cellularity, low mitotic count, and low Ki-67 index, which indicate
low risk, predict a more favorable DFS for small intestine GIST patients undergoing curative
resection. Absence of tumor perforation with low mitotic count and low cellularity, which indicates
low risk, can predict long-term OS for small intestine GIST patients who have undergone curative
resection.
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Background
Mesenchymal tumors of the gastrointestinal (GI) tract are
rare, comprising only 0.1% to 3% of all GI neoplasms [1].
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the GI tract. These
tumors are composed of tumor cells from the interstitial
cells of Cajal [2,3], which are considered to be GI pace-
maker cells.
Gain-of-function mutations in the c-kit proto-oncogene
and overexpression of the kit protein can occur [4,5], and
result in a constitutive stimulus to tumor cell growth.
Because the kit tyrosine kinase inhibitor imatinib
mesylate (Gleevec, formerly known as STI571, Novartis
Pharma AG, Basel, Switzerland) has been shown to pro-
duce a promising clinical result in an advanced GIST
patient [6], identification of GIST by kit immunopositiv-
ity has become paramount.
Surgical resection with a negative gross margin remains
the mainstay of therapy for primary GISTs. However,
recurrence is common, and the 5-year survival rate after
complete resection ranges from 40% to 65% [7-11]. Sev-
eral clinical and pathological factors that influence patient
survival have been reported, but the results have varied
due to variation in confirmation of kit [7-12]. Postopera-
tive follow-up and management for small intestine GISTs
after curative resection should be tailored to patients
according to high- or low-risk status of the tumors. Before
the era of imatinib mesylate, we identified 100 patients
with primary GISTs of the small intestine using positive
kit immunostaining. Our aim was to identify predictors
for long-term DFS and OS for small intestine GIST
patients and clarify the difference between low- and high-
risk patients after curative resection.
Methods
One hundred sixty-seven consecutive patients with mes-
enchymal tumors involving the small intestine were
treated at the Department of Surgery, Chang Gung Memo-
rial Hospital from January 1983 to December 2002. The
study was conducted with the approval of the institutional
ethics board of our hospital. We excluded (a) patients
with other intra-abdominal or retroperitoneal sarcomas
which directly invaded or metastasized to the small intes-
tine (such as uterine leiomyosarcoma, gastric GISTs, retro-
peritoneal sarcoma, etc.), (b) patients with other
concurrent malignancies at presentation, and (c) patients
with incidental findings on laparotomy (most had benign
leiomyoma, size < 2 cm and trace mitotic count).
Immunohistochemistry (IHC) analyses were performed
to identify immunophenotypes and reviewed blindly by
the authors (Wu TJ, Lee LY, Yeh CN, and Wu PU). Thirteen
of 113 patients who showed negative kit immunostaining
were excluded from the study including 5 patients with
leiomyomas, 3 with leiomyosarcomas, 1 with a schwan-
noma, 1 with an inflammatory fibroid polyp, 1 with a fol-
licular dendritic tumor, 1 with a malignant rhomboid
tumor, and 1 with a malignant histocystic sarcoma. One
hundred patients were diagnosed as having primary GISTs
of the small intestine according to established criteria
[13,14]. Clinicopathological features and follow-up status
of these patients were retrospectively reviewed.
Immunohistochemistry (IHC)
Four-µm sections from formalin-fixed, paraffin-embed-
ded tissue were stained for ICC-associated antigens (kit
and CD34) (Dako, Carpinteria, California, USA), myo-
genic antigen (smooth muscle actin [SMA]) (Dako,
Carpinteria, California, USA), neurogenic antigen (S-100)
(Dako, Carpinteria, California, USA), and tumor prolifer-
ation marker (Ki-67) (Dako, Carpinteria, California,
USA). A biotin/straptavdin-peroxidase complex detection
system (Dako, Carpinteria, California, USA) with diami-
nobenzidine (DAB) as the chromogen was used. Normal
small intestine was used as the internal control for kit,
SMA and S-100. The vascular endothelium was an internal
positive control for CD34, and small intestine mucosa
was an internal control for Ki-67. For IHC scoring, cells
with positive stains below 10% were regarded as negative,
10%–50% as focally positive, and over 50% as diffusely
positive. A Ki-67 index greater than 10% positively stained
nuclei in 50 randomly selected high power fields (HPF)
was defined as the cut line [15].
Prognosis analysis
Patients with distant metastases or multiple small tumors
involving whole small intestine (sarcomatosis) at presen-
tation were defined as advanced cases. A curative resection
was defined as the tumor having been completely
removed with a negative margin macroscopically. Recur-
rent disease was defined as the presence of a histologically
or radiographically demonstrated tumor. Distant meta-
static disease was defined as disease occurring at remote
structures. Regional intra-peritoneal disease was called
local recurrence if it involved a solitary recurrent tumor or
sarcomatosis.
The following clinical and pathological factors were cho-
sen for survival analysis: gender, age (<60 or 60 years),
operative time (elective, non-elective [urgent or emer-
gent]), operative procedure, location, tumor size (<2 cm,
2–5 cm, 5–10 cm, or 10 cm), mesenteric involvement,
local invasion to other intra-abdominal organs or perito-
neum, tumor perforation, cell type (spindle or mixed with
epithelioid cells), pleomorphism (low or high), mitotic
count (5 or >5 of 50 HPF), cellularity (low or high),
nuclear atypia, para-nuclear cytoplasmic vacuoles, skei-
noid fibers, inflammatory cell infiltration, tumor border,BMC Gastroenterology 2006, 6:29 http://www.biomedcentral.com/1471-230X/6/29
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tumor necrosis, mucosal invasion, ulceration, vascular
proliferation, microscopic resection margins, lymphatic
infiltration, immunophenotype (kit, CD34, SMA, and S-
100), and Ki-67 index (<10% or 10%).
Data were analyzed using SPSS software (version 10.0;
SPSS, Inc., Chicago, Illinois, USA). DFS and OS rates were
calculated using the Kaplan-Meier method. Survival was
calculated from the day of the histological diagnosis to the
closing date for the evaluation of follow-up, which was
December 31, 2003. The log-rank test was used for univar-
iate analysis and Cox's proportional hazard model was
used for multivariate analysis. P < 0.05 was considered sig-
nificant.
Results
Clinical characteristics
Fifty-two males and 48 females who ranged in age from
27 to 82 years (median: 56.5 years) were symptomatic at
presentation. The most common symptom was GI bleed-
ing (n = 84), followed by abdominal pain (n = 38), ane-
mia (n = 34), and palpable mass (n = 33). Peritonitis due
to tumor perforation was found in 12 patients.
Regarding tumor location, 19 tumors were located in the
duodenum (10 in the second portion; 6 in the third; and
3 in the fourth portion), 63 in the jejunum, and 17 in the
ileum. One patient, who presented with multiple tumors
distributed throughout the small intestine and mesentery,
was classified as undetermined location. Regarding the
jejunal tumors, most occurred in the proximal jejunum,
with a median distance of 30 cm from the Treiz ligament.
Most of the ilial tumors developed in the distal ileum,
with a median distance of 60 cm from the ileocecal junc-
tion. The largest tumor diameter ranged from 3 to 30 cm
(median: 8.8 cm).
Four commonly used diagnostic tools were computed
tomography (CT) (78%), panendoscopy (66%), upper GI
series (44%), and angiography (23%). Among the 78
patients who underwent CT, CT images revealed the pres-
ence of an intra-abdominal tumor in 71 patients, yielding
a sensitivity rate of 91.0%. Routine esophagogastroduo-
denoscopy was performed to evaluate patients with upper
GI bleeding, but only 11 of the 66 patients (16.7%) with
duodenal tumors had endoscopic abnormalities. The
upper GI series showed abnormal findings in 34 of the 44
tested patients (77.3%). Although half of the patients suf-
fered from melena, only 11 of the 23 patients (43.5%)
who underwent angiography had positive angiographic
findings.
Histopathologic features
Most tumors were composed of spindle cells (83%), and
some were mixed with epithelioid cells (17%). No purely
epithelioid picture was seen in our series. Tumor cells
were mostly uniform, but some revealed significant pleo-
morphisms (32%). Focal nuclear atypia was a common
feature (93%), with some tumors showing scattered
bizarre nuclei. However, para-nuclear cytoplasmic vacu-
oles (10%) and skeinoid fibers (14%) were rarely found.
Mitoses were common in the small intestine GISTs; 69%
of patients had a mitotic count > 5 per 50 HPF and 31%
of patients had a count 5 per 50 HPF. Coagulative necro-
sis (68%), mucosal ulceration (55%), and high cellularity
(43%) were usually found in the larger tumors (> 5 cm).
Most tumors were rich in vascular proliferation (90%),
and stromal hemorrhage was a common feature of these
tumors. Three patients had lymphatic infiltration.
With regard to staining distribution, most small intestine
GISTs (80/100; 80%) showed diffusely positive kit immu-
nostaining, and some showed focally positive immunos-
taining (20%). Most of the staining patterns showed
diffuse, strong cytoplasmic positivity (69%), and some
(31%) showed a mixed cytoplasmic dot-like pattern (the
so-called "golgi pattern"). Sixty-eight of 100 tumors
showed CD34 positivity, 35% showed myogenic differen-
tiation that was diffusely positive in SMA, and 24%
showed neurogenic differentiation that was diffusely pos-
itive for S-100 protein.
Treatment and outcomes
Among the 100 patients, 86 underwent segmental resec-
tion of the small intestine with the tumor and the
involved mesentery, peritoneum, retroperitoneum, or
other contiguous intra-abdominal organs. Six patients
with a tumor in the second portion of the duodenum
underwent the Whipple procedure, and the other 7
patients with isolated tumors underwent local excision.
The remaining patient, who presented with sarcomatosis,
underwent biopsy. Elective surgery was scheduled for 72
patients; for the other 28 patients non-elective (urgent or
emergent) operations were performed due to active tumor
bleeding, tumor perforation-related peritonitis, or intesti-
nal obstruction. There was no postoperative mortality in
this series; hospital stays ranged from 6 to 54 days
(median: 15 days). With a median follow-up of 33.2
months (range: 5–202 months), the OS rates for these
100 patients were 91.5% at 1 year, 66.6% at 3 years, and
50.5% at 5 years.
Curative resection was carried out in 85 patients. Of the
15 patients who did not undergo curative resection, 10
had liver metastasis, 4 had debulking resection due to
invasion of great vessels or vital organs, and 1 had open
biopsy for sarcomatosis. Patients who underwent curative
resection had a significantly longer median survival of
123.3 months (mean: 97.5 months; range: 5.5–202
months) compared with 12.0 months (mean: 21.4BMC Gastroenterology 2006, 6:29 http://www.biomedcentral.com/1471-230X/6/29
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months; range: 4–56 months) for those who had incom-
plete resection or distant metastasis at presentation. Of 85
patients who underwent curative resection, 44 (51.8%)
had recurrence. The median time of recurrence was 20.5
months (range: 3.7–125.1 months). The DFS rates were
85.2% at 1 year, 53.8% at 3 years, and 43.7% at 5 years.
Table 1 lists the sites of recurrence. Most cases of liver
metastasis were multiple. Only 4 patients with isolated
liver metastasis underwent hepatectomy. For the 44
patients with recurrence, median post-recurrent survival
was 7.9 months (range: 1.2–90 months). Complete re-
resection for recurrent disease was only achieved in 8
patients, with a median post-recurrence survival of 25.8
months. Chemotherapy (doxorubicin [adriamycin] and
dacarbazine [DTIC]) was given to 5 patients who had a
median survival of 3.6 months. Thirty-one patients with
recurrence were given supportive treatment. These
patients had a median survival of 5.9 months. Since 2002,
imatinib mesylate (Gleevec) has been administered for
unresectable GISTs in our hospital. Eight patients with
unresectable recurrent disease were given this therapy.
Survival analysis
Regarding clinical factors, large tumor size, advanced
tumor with local invasion to a contiguous organ, and
presence of tumor perforation predicted poor DFS (Table
2). Among pathological factors, mitotic count > 5 per 50
HPF, high cellularity, presence of tumor necrosis, and Ki-
67 index 10% predicted worse DFS (Tables 3 and 4).
However, multivariate survival analysis revealed that
tumor with high cellularity (Fig. 1A), mitotic count >5 per
50 HPF (Fig. 1B), and a Ki-67 index 10% (Fig. 1C) were
independent factors that predicted poor DFS (Table 5).
With regard to OS, presence of tumor perforation, mitotic
count >5 per 50 HPF, high cellularity, presence of tumor
necrosis, vascular proliferation, lymphatic infiltration,
and Ki-67 index 10% predicted worse OS by univariate
analysis (Tables 2, 3, and 4). However, presence of tumor
perforation (Fig. 1D), mitotic count >5 per 50 HPF (Fig.
1E), and tumor with high cellularity (Fig. 1F) independ-
ently predicted less favorable OS (Table 5).
Table 1: Sites of first recurrence in small intestine GIST patients 
who underwent curative resection
Recurrence site N % of total recurrence
Liver 35 79.5
Any 14 31.8
Only 21 47.7
Intra-abdominal 21 47.7
Any 13 29.5
Only 8 18.2
Lung 1 2.3
Bone 1 2.3
Table 2: Prognostic analysis of DFS and OS for GISTs of the small intestine in terms of clinical features
Variable Mean DFS (months; 
95%CI of mean)
P Mean OS (months; 
95%CI of mean)
P
Gender Male (N = 43) 60.0 (42.3–77.6) 0.2789 83.7 (63.0–105.5) 0.3171
Female (N = 42) 84.3 (53.3–115.3) 108.5 (77.8–139.1)
Age (years) 60 (N = 60) 66.9 (52.1–81.7) 0.3860 98.3 (79.57–117.1) 0.2646
> 60 (N = 25) 68.8 (34.0–103.6) 93.7 (53.3–134.0)
Operation time Elective (N = 61) 69.4 (46.6–92.1) 0.5463 100.5 (75.8–125.2) 0.6959
Non-elective (N = 24) 73.6 (51.3–96.0) 85.3 (61.8–108.8)
Operative procedure small intestine 
resection (N = 78)
68.3 (49.5–87.2) 0.1630 95.5 (74.8–116.2) 0.4290
local excision (N = 7) 77.0 (54.7–99.2) 76.2 (53.1–99.3)
Location Duodenum (N = 17) 52.3 (31.8–72.7) 0.6391 131.4(95.6–167.1) 0.5399
Jejunum (N = 52) 68.6 (53.2–84.0) 85.2 (67.1–103.3)
Ileum (N = 16) 66.8 (24.4–09.2) 96.4 (49.2–143.7)
Tumor size 2–5 cm (N = 15) 105.1 (79.1–131.) 0.0450 135.7 (101.2–170.2) 0.2413
5–10 cm (N = 36) 61.5 (42.5–80.6) 78.9 (53.3–104.5)
> 10 cm (N = 34) 67.6 (38.8–96.5) 99.8 (64.9–134.6)
Mesenteric 
involvement
no (anti-mesenteric 
site) (N = 38)
82.5 (48.7–116.3) 0.7648 108.6 (70.2–146.9) 0.6855
yes (mesenteric site) 
(N = 47)
62.3 (46.0–78.5) 89.6 (67.7–111.5)
Local invasion No (N = 65) 82.4 (56.5–108.3) 0.0169 102.9 (76.8–129.0) 0.7962
Yes (N = 20) 41.9 (20.6–63.2) 90.1(60.7–119.5)
Tumor perforation No (N = 75) 75.7 (55.0–96.5) 0.0485 102.7 (80.8–124.8) 0.0594
Yes (N = 10) 30.5 (15.1–45.9) 44.3 (29.7–59.0)
DFS = disease-free survival; OS = overall survival; GISTs = gastrointestinal stromal tumorsBMC Gastroenterology 2006, 6:29 http://www.biomedcentral.com/1471-230X/6/29
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Discussions and conclusions
Gastrointestinal stromal tumors (GISTs) comprise the
great majority of primary mesenchymal tumors of the gas-
trointestinal (GI) tract. The small intestine is the second
most common site of occurrence [9-11,17-21]. Prognosis
for patients with GISTs depends to some extent on the
anatomic site of tumor location. According to some
authors, there is a trend for small intestine tumors to have
the worst prognosis and esophageal tumors the best
[10,20]. However, some other authors have concluded
that the behavior of GISTs is similar regardless of site
[10,12,21]. Due to the controversy over the topic of ana-
tomic variation, we focused specifically on GISTs of the
small intestine. We retrospectively reviewed 100 GISTs
with c-kit immunopositivity at one institution over two
decades. This study is one of the largest series [20,24-26],
especially before the imatinib mesylate era.
The 1-, 3-, and 5-year DFS rates following curative resec-
tion in our study were 85.2%, 53.8%, and 43.7%, respec-
tively, which are similar to those in DeMatteo's report [11]
and better than those reported by Crosby et al [20]. The
OS rate was 50.5% at 5 years, which is similar to rates
reported in the literature which range from 40% to 65%
[8-11,22]. In this study, we used univariate and multivar-
iate analysis to analyze DFS and OS for patients with
small bowel GISTs after curative resection with regard to
numerous clinicopathologic factors. The results can be
used to clarify the difference between high- and low-risk
patients after curative resection to further tailor follow-up
programs and treatment plans.
In univariate analysis, tumor size, local invasion, tumor
perforation, mitotic count, tumor cellularity, tumor
necrosis, and Ki-67 index significantly influenced DFS in
patients with small intestine GISTs after curative resection.
Also, tumor size, tumor perforation, mitotic count, tumor
cellularity, tumor necrosis, vascular proliferation, lym-
phatic infiltration, and Ki-67 index significantly influ-
enced OS. Application of the multivariate Cox proportion
Table 3: Prognostic analysis of DFS and OS for GISTs of the small intestine in terms of histopathological features
Variable Mean DFS (months; 
95%CI of mean)
P Mean OS (months; 95%CI of 
mean)
P
Cell type Spindle (N = 71) 75.1 (52.9–97.3) 0.1708 99.0(77.6–120.3) 0.3355
Mixed with epithelioid tumor 
(N = 14)
59.5 (27.8–91.2) 76.8 (40.3–113.2)
Pleomorphism Low (N = 61) 56.6 (51.6–106.1) 0.1914 123.3 (78.1–127.5) 0.2970
High (N = 24) 25.1 (32.2–79.6) 76.9 (52.0–101.9)
Mitotic count  5 of 50 HPF (N = 30) 182.3 (157.0–208.6) < 0.0001 182.4 (156.68–208.2) 0.0002
> 5 of 50 HPF (N = 55) 43.7 (31.8–55.7) 73.8 (55.7–91.9)
Cellularity Low (N = 53) 103.6 (71.8–135.5) < 0.0001 127.9 (98.5–157.4) 0.0001
High (N = 32) 37.0 (20.1–53.8) 65.2 (42.3–88.1)
Nuclear atypia Absence (N = 7) 71.8 (28.8–114.7) 0.4393 123.8 (37.5–210.2) 0.4685
Presence (N = 78) 71.4 (51.3–91.6) 95.6 (72.5–18.6)
Para-nuclear 
cytoplasmic
Absence (N = 76) 69.6 (50.6–88.7) 0.4853 95.5 (74.9–116.1) 0.3995
vacuoles Presence (N = 9) 43.7 (30.1–57.3) 54.6 (42.7–66.5)
Skeinoid fibers Absence (N = 72) 70.1 (50.6–89.7) 0.5636 95.3 (74.4–16.2) 0.4664
Presence (N = 13) 50.4 (31.9–68.9) 63.8 (48.5–9.1)
Inflammatory cell Absence (N = 65) 72.2 (52.1–92.3) 0.5754 98.0 (76.4–119.6) 0.7927
infiltration Presence (N = 20) 59.7 (33.6–85.9) 107.4 (54.6–103.2)
Tumor border Infiltrating (N = 52) 88.6 (60.9–116.2) 0.2937 106.2 (77.9–137.0) 0.1884
well-circumscribed (N = 33) 71.7 (53.2–90.1) 130.1 (82.7–129.7)
Tumor necrosis Absence (N = 29) 131.1(82.3–179.9) 0.0061 148.3 (98.3–198.3) 0.0122
Presence (N = 56) 53.8 (40.3–67.2) 82.2 (64.0–100.4)
Mucosal invasion Absence (N = 54) 69.7 (46.0–93.5) 0.3993 99.8 (74.6–125.1) 0.9839
Presence (N = 31) 69.2 (47.2–91.2) 83.3 (59.9–106.78)
Ulceration Absence (N = 37) 78.9 (50.9–106.9) 0.4623 105.4 (76.3–134.4) 0.3830
Presence (N = 48) 59.1 (43.6–74.6) 80.2 (62.8–97.6)
Vascular proliferation Absence (N = 9) 130.4 (56.8–204.0) 0.0889 82.0 (154.3–209.8) 0.0192
Presence (N = 76) 61.9 (49.4–4.5) 83.4 (68.6 – 98.3)
Microscopic resection Negative (N = 81) 72.2 (52.71–91.8) 0.5059 97.9 (77.3–118.6) 0.6561
margins Positive (N = 4) 22.8 (17.1– 28.53) 30.6 (22.0–39.1)
Lymphatic infiltration Absence (N = 83) 72.9 (53.3–92.6) 0.0768 99.8 (78.8–120.7) 0.0218
Presence (N = 2) 19.8 (0.0–46.7) 29.1(14.6–43.6)
DFS = disease-free survival; OS = overall survival; GISTs = gastrointestinal stromal tumorsBMC Gastroenterology 2006, 6:29 http://www.biomedcentral.com/1471-230X/6/29
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hazard model revealed that long-term DFS was only
dependent on tumor with low cellularity, low mitotic
count, and low Ki-67 index. Long-term OS was dependent
on no tumor perforation, low mitotic count, and low cel-
lularity.
With regard to local invasion and tumor perforation, a
tumor that has invaded a contiguous organ is considered
to be advanced and associated with poor outcome [8-10].
Local invasion and tumor perforation were associated
with poor DFS; although all gross disease was removed,
these conditions were similar to those that occur with
incomplete resections [10]. Similarly, local invasion and
tumor perforation were not independent factors for DFS,
but tumor perforation was an independent significant
predictor for poor OS.
Table 5: Multivariate analysis of significant clinical, pathological, and immunohistochemical features influencing the DFS and OS in 85 
patients with malignant GISTs of the small intestine who underwent curative resection
Variable Relative risk 95% CI for relative risk P value
DFS
Tumor size (2–5, 5–10, and >10 
cm)
NS
Local invasion NS
Tumor perforation NS
Mitotic count >5 per 50 HPF 11.36 2.653–50.0 0.001
High cellularity 2.004 1.036–3.876 0.039
Tumor necrosis NS
Ki-67 index 3.460 1.1.195 0.049
OS
Tumor size (2–5, 5–10, and >10 
cm)
NS
Tumor perforation 3.058 1.20–7.81 0.019
Mitotic count >5 per 50 HPF 6.711 1.50–30.30 0.013
High cellularity 2.370 1.11–5.08 0.026
Tumor necrosis NS
Vascular proliferation NS
Lymphatic infilatration NS
Ki-67 index 10% NS
DFS = disease-free survival; OS = overall survival; GISTs = gastrointestinal stromal tumors; CI = confidence interval
Table 4: Prognostic analysis of DFS and OS for GISTs of the small intestine in terms of immunohistochemical features
Variable Mean DFS (ms; 95%CI 
of mean)
P Mean OS (ms; 95%CI 
of mean)
P
CD117 (KIT) Focally positive (N = 12) 40.1 (18.3–61.9) 0.1276 77.8 (39.9–115.6) 0.2159
Diffusely positive (N = 73) 74.4 (54.0–94.7) 101.6 (79.1–124.3)
KIT immunopattern Diffuse cytoplasmic stain (N = 55) 80.8 (54.6–107.0) 0.0981 95.5 (70.9–120.1) 0.8628
Mixed with "golgi pattern" (N = 30) 51.6 (33.1– 70.1) 99.4 (69.1–129.7)
CD34 Negative (N = 25) 64.8 (44.9–84.6) 0.4806 87.5 (64.7–110.4) 0.2242
Focally positive (N = 28) 55.9 (34.6–77.2) 70.6 (48.2–93.0)
Diffusely positive (N = 32) 81.0 (50.6–111.4) 116.9 (84.4–149.2)
SMA Negative (N = 36) 76.3 (44.4–108.3) 0.1866 101.2 (70.5–132.0) 0.0637
Focally positive (N = 17) 45.4 (24.3– 66.5) 56.8 (34.6–78.9)
Diffusely positive (N = 32) 82.0 (60.7–103.2) 106.8 (82.2–131.4)
S-100 Negative (N = 34) 81.9 (49.9–113.9) 0.1274 104.9 (75.8–133.9) 0.3896
Focally positive (N = 31) 64.5 (44.6–84.5) 79.8 (60.6–99.0)
Diffusely positive (N = 20) 48.4 (22.43–74.3) 78.6 (43.4–113.9)
Ki-67 index < 10% (N = 80) 73.6 (53.9–93.4) 0.0014 99.4 (78.5–120.2) 0.0171
10% (N = 5) 13.8 (6.8–20.8) 24.0 (13.0–35.0)
DFS = disease-free survival; OS = overall survival; GISTs = gastrointestinal stromal tumorsBMC Gastroenterology 2006, 6:29 http://www.biomedcentral.com/1471-230X/6/29
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Tumor size was one of factors that predicted prognosis for
GIST in a consensus report [13], which defined high risk
if tumor size was more than 10 cm and intermediate risk
if tumor size ranged from 5 to 10 cm. However, tumor size
was not an independent risk factor in our study. It might
be there was patient selection bias in this study, in which
most of the patients who received surgical treatment were
symptomatic and had a large tumor (median tumor size
was 8.8 cm, range from 3 to 30 cm). It also might be
biased because of the poor prognosis of small intestine
GIST, in which tumor size over 5 cm is defined as proba-
bly malignant [27]. Therefore, there is no significant dif-
ference between tumors of size >10 cm and tumors from
5 to 10 cm in size.
Mitotic count < 5/50 HPF, low cellularity, no tumor
necrosis, and low Ki-67 index were associated with favora-
ble DFS, but only mitotic count >5/50 HPF and high Ki-
67 index had a significant adverse influence on DFS. Some
authors have also proposed that high histopathologic
grade adversely affects prognosis of gastrointestinal sar-
coma [8-10]. GISTs of the small intestine with histopatho-
logic features including mitotic counts >5/50 HPF, high
cellularity, absence of a predominant organoid growth
pattern, absence of skeinoid fibers, presence of severe
nuclear pleomorphism, presence of mucosal infilatration,
and tumor cell necrosis have been significantly associated
with an adverse outcome in the literature [24-26]. How-
ever, Crosby et al. [20] found no correlation between
tumor grade and clinical behavior in 50 GISTs of the small
intestine. In the present study, mitotic count >5/50 HPF
was the most important independent factor predicting
poor DFS and OS. Similar to Miettinen's report, kit immu-
nopositivity, staining patterns, and histologic subtype did
not correlate with prognosis [21]. Ki-67 immunoreactivity
appears to be a valid measure of tumor cell proliferation
and has been related to outcome in patients with GISTs in
a number of studies [22,23]. Tumors with more than 10%
of nuclei positive for Ki-67 analogs developed metastases
more easily and had higher tumor-related mortality [15].
Disease-free survival for 85 patients with small bowel gastrointestinal stromal tumor (GIST) who underwent curative resection  in terms of (A) mitotic count; (B) tumor cellularity; (C) Ki-67 index; and overall survival for 85 patients with small bowel GIST  who underwent curative resection in terms of (D) tumor perforation; (E) mitotic count; (F) cellularity Figure 1
Disease-free survival for 85 patients with small bowel gastrointestinal stromal tumor (GIST) who underwent curative resection 
in terms of (A) mitotic count; (B) tumor cellularity; (C) Ki-67 index; and overall survival for 85 patients with small bowel GIST 
who underwent curative resection in terms of (D) tumor perforation; (E) mitotic count; (F) cellularity.
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In the present study, Ki-67 score 10% was also an inde-
pendent factor associated with poorer DFS, however, it
was not an independent factor for OS. Mitotic count is
superior to Ki-67 index analogs in the evaluation of GIST
with regard to DFS and OS.
In conclusion, small tumor size with low mitotic counts
and low Ki-67 index, indicating low risk, predicted more
favorable DFS of small intestine GIST patients who under-
went curative resection. Absence of tumor perforation
with low mitotic count and low cellularity, indicating low
risk, predicted long-term OS of small intestine GIST
patients who underwent curative resection.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
TJW carried out manuscript writing and analyzing the
data. LYL performed IHC staining and interpreting the
result of IHC. CNY instructed manuscript writing. PYW
helped specimen collection and IHC staining. TCC, TLH,
YYJ, and MFC discussed the manuscript writing and statis-
tical result.
Acknowledgements
We acknowledged Ms Shu-Fang Huang for her help to do the statistical 
analysis.
References
1. Lewis JJ, Brennan MF: Soft tissue sarcoma.  Curr Prob Surg 1996,
33:817-872.
2. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM: Gas-
trointestinal pacemaker cell tumor (GIPACT): Gastrointes-
tinal stromal tumors show phenotypic characteristics of the
interstitial cells of Cajal.  Am J Pathol 1998, 152:1259-1269.
3. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell
RH: Interstitial cells of Cajal as precursors of gastrointestinal
stromal tumors.  Am J Surg Pathol 1999, 23:377-389.
4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S,
Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G,
Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-func-
tion mutations of c-kit in human gastrointestinal stromal
tumors.  Science 1998, 279:577-580.
5. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S,
Singer S, Fletcher CD, Fletcher JA: KIT extracellular and kinase
domain mutations in gastrointestinal stromal tumors.  Am J
Pathol 2000, 156:791-795.
6. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahar-
tiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker
B, Demetri GD: Effect of tyrosine kinase inhibitor DTI571 in a
patient with a metastatic gastrointestinal stromal tumor.  N
Engl J Med 2001, 344:1052-1056.
7. Akwari OE, Dozois RR, Weiland LH, Bearhrs OH: Leiomyosar-
coma of the small and large bowel.  Cancer 1978, 42:1375-1384.
8. Shiu MH, Farr GH, Papchristou DN, Hajdu SI: Myosarcoma of the
stomach: nature history, prognostic factors and manage-
ment.  Cancer 1982, 49:177-187.
9. McGrath PC, Neifeld JP, Lawrence W Jr, Kay S, Horsley JS 3rd, Parker
GA: Gastrointestinal sarcomas. Analysis of prognostic fac-
tors.  Ann Surg 1987, 206:706-710.
10. Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM: Prog-
nostic factors influencing survival in gastrointestinal leiomy-
osarcoma. Implications for surgical management and
staging.  Ann Surg 1992, 215:68-77.
11. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan
MF: Two hundred gastrointestinal stromal tumors: Recur-
rence patterns and prognostic factors for survival.  Ann Surg
2000, 231:51-57.
12. Ng EH, Pollock RE, Romsdahi MM: Prognostic implications of
patterns of failure for gastrointestinal leiomyosarcomas.
Cancer 1992, 69:1334-1341.
13. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ,
Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin
LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors.
A consensus approach.  Hum Pathol 2002, 33:459-465.
14. Rudolph P, Gloeckner K, Parwaresch R, Harms D, Schmidt D:
Immunophenotype, proliferation, DNA-ploidy, and biologi-
cal behavior of gastrointestinal stromal tumors: A multivar-
iate clinicopathologic study.  Hum Pathol 1998, 29:791-800.
15. Dougherty MJ, Compton C, Talbert M, Wood WC: Sarcomas of
the gastrointestinal tract: separation into favorable and
unfavorable groups by mitotic count.  Ann Surg 1991,
214:569-574.
16. He LJ, Wang BS, Chen CC: Smooth muscle tumors of the diges-
tive tract: report of 160 cases.  Br J Surg 1988, 75:184-186.
17. Chou FF, Eng HL, Sheen-Chen SM: Smooth muscle tumors of the
gastrointestinal tract: analysis of prognostic factors.  Surgery
1996, 119:171-177.
18. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gas-
trointestinal smooth-muscle (stromal) tumors: dependence
on anatomic site.  Am J Surg Pathol 1999, 23:82-87.
19. Yao KA, Talamonti MS, Langella RL, Schindler NM, Rao S, Small W Jr,
Joehl RJ: Primary gastrointestinal sarcomas: analysis of prog-
nostic factors and results of surgical management.  Surgery
2000, 128:604-612.
20. Crosby JA, Catton CN, Davis A, Couture J, O'Sullivan B, Kandel R,
Swallow CJ: Malignant gastrointestinal stromal tumors of the
small intestine: a review of 50 cases from a prospective data-
base.  Ann Surg Oncol 2001, 8:50-59.
21. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy
H, Burke A, Sobin LH, Lasota J: Gastrointestinal stromal tumors,
intramural leiomyomas, and leiomyosarcomas in the duode-
num: a clinicopathologic, immunohistochemical, and molec-
ular genetic study of 167 cases.  Am J Surg Pathol 2003,
27:625-641.
22. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S: Gastrointestinal
stromal tumor: consistent CD117 immunostaining for diag-
nosis, and prognostic classification based on tumor size and
MIB-1 grade.  Hum Pathol 2002, 33:669-676.
23. Seidal T, Edvardsson H: Expression of c-kit (CD117) and Ki67
provides information about the possible cell of origin and
clinical course of gastrointestinal stromal tumours.  Histopa-
thology 1999, 34:416-424.
24. Brainard JA, Goldblum JR: Stromal tumors of the jejunum and
ileum: a clinicopathologic study of 39 cases.  Am J Surg Pathol
1997, 21:407-416.
25. Tworedk JA, Appelman HD, Singleton TP, Greenson JK: Stromal
tumors of the jejunum and ileum.  Mod Pathol 1997, 10:200-209.
26. Chang MS, Choe G, Kim WH, Kim YI: Small intestinal stromal
tumors: a clinicopathologic study of 31 tumors.  Pathol Int 1998,
48:341-347.
27. Miettinen M, El-Rifai W, HL Sobin L, Lasota J: Evaluation of malig-
nancy and prognosis of gastrointestinal stromal tumors: a
review.  Hum Pathol 2002, 33:478-483.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-230X/6/29/pre
pub